NeuroPace, Inc.

NasdaqGM NPCE

NeuroPace, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 4.62

NeuroPace, Inc. Price to Sales Ratio (P/S) is 4.62 on January 14, 2025, a -7.08% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

NeuroPace, Inc. 52-week high Price to Sales Ratio (P/S) is 7.27 on February 20, 2024, which is 57.21% above the current Price to Sales Ratio (P/S).
NeuroPace, Inc. 52-week low Price to Sales Ratio (P/S) is 2.26 on October 23, 2024, which is -51.17% below the current Price to Sales Ratio (P/S).
NeuroPace, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 4.05.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: NPCE

NeuroPace, Inc.

CEO	Mr. Joel D. Becker
IPO Date	April 22, 2021
Location	United States
Headquarters	455 North Bernardo Avenue
Employees	184
Sector	Health Care
Industries Pharmaceuticals Telehealth Virtual Reality (VR)

Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Key trends

Past 5 years